Safety of Allogeneic Hematopoietic Cell Transplant in Adults After Cd19 Targeted Chimeric Antigen Receptor-Modified T-Cell (Car-T) Therapy

Hematological Oncology - United Kingdom
doi 10.1002/hon.122_2630
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Cytokine Release Syndrome and Neurotoxicity After CD19 Chimeric Antigen Receptor-Modified (CAR-) T Cell Therapy

British Journal of Haematology
Hematology
2018English

Haemophagocytic Lymphohistiocytosis Has Variable Time to Onset Following CD19 Chimeric Antigen Receptor T Cell Therapy

British Journal of Haematology
Hematology
2019English

Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors

Molecular Therapy - Oncolytics
Cancer ResearchOncologyMolecular MedicinePharmacology
2016English

Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma

International Journal of Hematology
Hematology
2020English

Advancing Chimeric Antigen Receptor T Cell Therapy With CRISPR/Cas9

Protein & Cell
BiochemistryBiotechnologyDrug DiscoveryCell BiologyMedicine
2017English

Cytokine Release Syndrome With Chimeric Antigen Receptor T Cell Therapy

Biology of Blood and Marrow Transplantation
TransplantationHematology
2019English

Novel BAFF-R CAR T-Cell Therapy for CD19 Antigen-Loss Relapsed B Cell Tumors

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

An Introduction to Chimeric Antigen Receptor (CAR) T Cell Immunotherapy for Human Cancer

American Journal of Hematology
Hematology
2019English

Rapid Relapse of Large B‐Cell Lymphoma After CD19 Directed CAR‐T‐Cell Therapy Due to CD‐19 Antigen Loss

American Journal of Hematology
Hematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy